Coherus Biosciences (CHRS) Upgraded to “Hold” at BidaskClub

BidaskClub upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a sell rating to a hold rating in a research note published on Thursday.

A number of other research firms have also commented on CHRS. ValuEngine upgraded shares of Coherus Biosciences from a strong sell rating to a sell rating in a report on Friday, September 1st. Zacks Investment Research lowered shares of Coherus Biosciences from a hold rating to a sell rating in a report on Tuesday, October 10th. Maxim Group reiterated a buy rating and set a $20.00 price target (down from $40.00) on shares of Coherus Biosciences in a report on Friday, September 8th. Credit Suisse Group restated an outperform rating and issued a $17.00 price objective (down from $24.00) on shares of Coherus Biosciences in a report on Wednesday, September 27th. Finally, Cowen restated an outperform rating and issued a $45.00 price objective on shares of Coherus Biosciences in a report on Friday, September 8th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Coherus Biosciences currently has a consensus rating of Buy and a consensus target price of $30.00.

Shares of Coherus Biosciences (CHRS) traded up $0.05 during trading on Thursday, hitting $9.50. 537,500 shares of the stock were exchanged, compared to its average volume of 597,093. Coherus Biosciences has a 12 month low of $8.05 and a 12 month high of $29.59. The company has a debt-to-equity ratio of 1.84, a current ratio of 5.46 and a quick ratio of 5.46.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative net margin of 73.89% and a negative return on equity of 582.31%. equities research analysts forecast that Coherus Biosciences will post -4.39 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its position in shares of Coherus Biosciences by 171.0% in the 1st quarter. Bank of America Corp DE now owns 18,308 shares of the biotechnology company’s stock worth $387,000 after buying an additional 11,553 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of Coherus Biosciences by 20.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 161,366 shares of the biotechnology company’s stock worth $2,316,000 after buying an additional 27,064 shares during the period. Rhumbline Advisers grew its position in shares of Coherus Biosciences by 16.9% in the 2nd quarter. Rhumbline Advisers now owns 42,282 shares of the biotechnology company’s stock worth $607,000 after buying an additional 6,105 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Coherus Biosciences in the 2nd quarter worth about $4,850,000. Finally, SG Americas Securities LLC grew its position in shares of Coherus Biosciences by 32.7% in the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock worth $104,000 after buying an additional 1,785 shares during the period. Institutional investors and hedge funds own 81.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Coherus Biosciences (CHRS) Upgraded to “Hold” at BidaskClub” was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/22/coherus-biosciences-chrs-upgraded-to-hold-at-bidaskclub.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit